drugset / Trial / NCT05304936
HCW9218 for Advanced Pancreatic Cancer
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.
Timeline
- Start
- 2022-10-17
- Primary completion
- 2025-02-15
- Completion
- 2025-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HCW9218 | Protein / enzyme biologic | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
Indications
No indication recorded.